Corporations
make a difference

Read more

Treatment

The ARSACS Foundation is now
working with pharmaceutical companies
to develop a treatment for ARSACS

Read more

Several research projects
are currently funded
by the Foundation
in Canada and abroad

Read more

The Ataxia gene can be
passed through many generations
without manifesting any symptoms

Read more

We need your support
to pursue research that heals

How can you help?

Donate
`

Latest News

Spring

2015

ARSACS Research Funding for 2015-2016

The Foundation will provide again this year grants to researchers interested in ARSACS. The research grant could be as high as $100,000 for a 12 month period. If you are interested, please submit the required documents and the attached application form by May 22, 2015. See Financing Offer
Read more

Feb

27

2015

Discussions with an american cie

Preliminary discussions are underway with an american pharmaceutical cie to test a drug for ARSACS (preclinical trial). More information to follow.

Feb

19

2015

ARSACS researchers part of the E-Rare3 competition

A consortium of ARSACS researchers from several countries (Canada, Germany, Netherlands, France, Italy and Turkey) file a letter of intent as part of the E-Rare3 competition. More information to follow.

Feb

03

2015

Olivier Audet's study results available soon

Olivier Audet will present the results of his study at the Congrès de l’Association Québécoise des Sciences de l’Activité Physique – AQSAP Québec 2015 will be held on February 6 and 7 at Laval University. His study, funded by the Foundation, is to determine the impact of a regular training program on the physical condition and symptoms of spasticity on ARSACS patients.

Jan

20

2015

Audrey and Danny's initiative raised $1050 for ARSACS research

Audrey Bouchard and Danny Laberge took advantage of the holiday season to sell Christmas cakes. Their initiative raised $1050 for ARSACS research. Thank you to both of you and to your family members and friends in Saguenay and Pont-Rouge for your support to the cause.

Jan

16

2015

Chronic studies in ARSACS mice to be conducted

Activities are currently underway to conduct chronic studies on the administration of a drug in ARSACS mice. A preliminary study was done in 2013 and had positive results. This time, the studies will be done over a longer period of time. More details to come.

Jan

13

2015

2015 "European Research Projects on Rare Diseases" Joint Transnational Call

CIHR Institute of Genetics to participate in the 2015 "European Research Projects on Rare Diseases" Joint Transnational Call.

Read More

Jan

08

2015

International Ataxia Research Conference in March 2015

The International Ataxia Research Conference (ARC) will be held from March 25th to 28th,2015 at the Beaumont Estate, Windsor, UK. Prior to the conference,an ARSACS meeting will be held at the same location on March 23rd to discuss the outcome measures in ARSACS


Who We Are


What We Do

Funding
Funding
process
Team
Research
Research
process
Discovery
Trials
Trials

The Ataxia Charlevoix-Saguenay Foundation is a charitable organisation supported entirely by private donations. Different events are organised during the year by families, friends and community groups to raise funds to support research on ARSACS.


Since its creation, the Foundation has been successful in assembling a great team at all levels of the organisation (board, advisors, researchers, contributors and partners). The researchers are well respected in their field and have an international reputation for excellence.


The main research objective of the Ataxia Charlevoix-Saguenay Foundation is to develop a treatment for ARSACS. Several research projects on ARSACS are currently funded by the Foundation in Canada and abroad. Over 98% of the funds raised are allocated to research.


The main research objective of the Ataxia Charlevoix-Saguenay Foundation is to develop a treatment for ARSACS.


The first therapeutic tests on transgenic ARSACS mice conducted in the Spring 2013 were very positive. For a short study, the tests demonstrated some beneficial effect on the physical performance of the mice. Discussions are underway to determine the next step.